351 related articles for article (PubMed ID: 34448148)
21. Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Simpson E; Hamilton J; Pollard D; Clowes M; Kaltenthaler E; Meiklejohn D; Morley N
Pharmacoeconomics; 2019 Mar; 37(3):333-343. PubMed ID: 30246228
[TBL] [Abstract][Full Text] [Related]
22. Ustekinumab for Treating Moderately to Severely Active Crohn's Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Hodgson R; Walton M; Biswas M; Mebrahtu T; Woolacott N
Pharmacoeconomics; 2018 Apr; 36(4):387-398. PubMed ID: 29192397
[TBL] [Abstract][Full Text] [Related]
23. Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Wijnen B; Witlox W; Wolff R; Fayter D; Ramaekers B; Otten T; Ryder S; Posadzki P; Worthy G; Stirk L; Armstrong N; Kleijnen J; Joore M
Pharmacoeconomics; 2023 Jan; 41(1):33-42. PubMed ID: 36301414
[TBL] [Abstract][Full Text] [Related]
24. Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
Rose M; Shepherd J; Harris P; Pickett K; Lord J
Pharmacoeconomics; 2018 Nov; 36(11):1299-1308. PubMed ID: 29691773
[TBL] [Abstract][Full Text] [Related]
25. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
26. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R
Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
[TBL] [Abstract][Full Text] [Related]
27. The Clinical and Cost Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis: A Critique of the Evidence.
O'Connor J; Rice S; Smith A; Rodgers M; Lopez RR; Craig D; Woolacott N
Pharmacoeconomics; 2016 Apr; 34(4):337-48. PubMed ID: 26818809
[TBL] [Abstract][Full Text] [Related]
28. Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Grimm SE; Fayter D; Ramaekers BLT; Petersohn S; Riemsma R; Armstrong N; Pouwels X; Witlox W; Noake C; Worthy G; Kleijnen J; Joore MA
Pharmacoeconomics; 2019 Oct; 37(10):1195-1207. PubMed ID: 30895564
[TBL] [Abstract][Full Text] [Related]
29. Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Ramaekers BLT; Riemsma R; Tomini F; van Asselt T; Deshpande S; Duffy S; Armstrong N; Severens JL; Kleijnen J; Joore MA
Pharmacoeconomics; 2017 Feb; 35(2):191-202. PubMed ID: 27566699
[TBL] [Abstract][Full Text] [Related]
30. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
31. Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Witlox WJA; van Asselt ADI; Wolff R; Armstrong N; Worthy G; Chalker A; Buksnys T; Stirk L; Kleijnen J; Joore MA; Grimm SE
Pharmacoeconomics; 2020 Apr; 38(4):317-324. PubMed ID: 31814080
[TBL] [Abstract][Full Text] [Related]
32. Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Grimm SE; Armstrong N; Ramaekers BLT; Pouwels X; Lang S; Petersohn S; Riemsma R; Worthy G; Stirk L; Ross J; Kleijnen J; Joore MA
Pharmacoeconomics; 2019 May; 37(5):655-667. PubMed ID: 30293207
[TBL] [Abstract][Full Text] [Related]
33. Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal.
Thielen FW; Büyükkaramikli NC; Riemsma R; Fayter D; Armstrong N; Wei CY; Huertas Carrera V; Misso K; Worthy G; Kleijnen J; Corro Ramos I
Pharmacoeconomics; 2019 Aug; 37(8):975-984. PubMed ID: 30547368
[TBL] [Abstract][Full Text] [Related]
34. Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Fleeman N; Abdulla A; Bagust A; Beale S; Richardson M; Stainthorpe A; Boland A; Kotas E; McEntee J; Palmer D
Pharmacoeconomics; 2018 Mar; 36(3):289-299. PubMed ID: 29178025
[TBL] [Abstract][Full Text] [Related]
35. Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Al Khayat MNMT; Armstrong N; Howick J; O'Meara S; Posadzki P; Ryder S; Ahmadu C; Konings SRA; Postma MJ; Duffy S; Wolff RF; van Asselt ADI
Pharmacoeconomics; 2023 Apr; 41(4):353-361. PubMed ID: 36757608
[TBL] [Abstract][Full Text] [Related]
36. Rituximab for the treatment of rheumatoid arthritis.
Bagust A; Boland A; Hockenhull J; Fleeman N; Greenhalgh J; Dundar Y; Proudlove C; Kennedy T; Moots R; Williamson P; Dickson R
Health Technol Assess; 2009 Sep; 13 Suppl 2():23-9. PubMed ID: 19804686
[TBL] [Abstract][Full Text] [Related]
37. Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis.
Connock M; Tubeuf S; Malottki K; Uthman A; Round J; Bayliss S; Meads C; Moore D
Health Technol Assess; 2010 Oct; 14(Suppl. 2):1-10. PubMed ID: 21047485
[TBL] [Abstract][Full Text] [Related]
38. Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ren S; Squires H; Hock E; Kaltenthaler E; Rawdin A; Alifrangis C
Pharmacoeconomics; 2019 Sep; 37(9):1073-1080. PubMed ID: 30547369
[TBL] [Abstract][Full Text] [Related]
39. Filgotinib in Rheumatoid Arthritis: A Profile of Its Use.
Kim ES; Keam SJ
Clin Drug Investig; 2021 Aug; 41(8):741-749. PubMed ID: 34304373
[TBL] [Abstract][Full Text] [Related]
40. Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal.
Pennington B; Ren S; Barton S; Bacelar M; Edwards SJ
Pharmacoeconomics; 2019 Aug; 37(8):985-993. PubMed ID: 30465228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
